US Weekly IPO and SPAC Monitor: Gene editing Biotech Prime Medicine and Molybdenum Enricher Aerodynamic Separation Process

We are seeing a little activity in IPO land. A few deals are scheduled to price in the week ahead, and many still on the back burner. Gene editing biotech Prime Medicine (PRME) would be the first sizable IPO of the fourth quarter. Aerodynamic Separation Process (ASP) focusing on the commercialization of enriched Molybdenum-100 plans to list. Three holdovers from the past week are scheduled to price; Beamr Imaging (BMR), Intensity Therapeutics (INTS) and Alopexx (ALPX). Intel’s Mobileye (MBLY) will … Continue reading “US Weekly IPO and SPAC Monitor: Gene editing Biotech Prime Medicine and Molybdenum Enricher Aerodynamic Separation Process”